Does it take 2 yrs to slide a one liner in a presentation recently where he causally mentions there was some issue related to the injection needle blockage by the psi material? Sorry it is pathetic. Do not tell me, they have not known this for a long time. Anyone catch that blockage line in his pathetic presentation?
Are you a paid pumper or just waiting for the crumbs the mgmt leaves you behind? Or are you Bev? Either ways I do not care. You think 125M i big deal? Can you do the math and tell me how many free shares or nearly free shares did the mgmt get in the past 10 years you have been holding this bag and how many of those shares the mgmt still owns?
Who is the loser? I give and gave the mgmt enough rope now it is time to call the hangman.
At some point the shareholders (us) need to start making a little noise.
How many shares do you have BTW - you pumper? I have just under 1% of float - and yes I am #$%$ at the incompetence.
So #$%$ if you cannot handle the management being bashed here. If I were to see the Mgmt face to face I would have the same things to tell them.
And No. I will not sell, I will keep posting and keep writing to Bev and the Mgmt because they are not leveling with the shareholders. They cannot make presentations in middle of 2013 and claim they should have pre-clinical study results (as expected by an avg. investor in about 6 months), this has taken nearly 2 years and they have nothing to show for it.
Paul made one passing statement about the needle and the material clogging the needle in his last presentation. Seriously, they need to man up and tell us what the f is going on.
Tethadur animal studies were expected to be announced in 2013. (See SeekingAlpha), it is now Dec. 2014 and I aint seen nothing yet.
I am pasting this from SeekingAlpha - Avid Research wrote this on Aug 15, 2013.
One of the 2013 milestones listed by pSivida in the June investor presentation is to release "pre-clinical peptide and protein delivery data." So, I expect additional Tethadur pre-clinical data later this year (2013). pSivida has 3 tech evaluations ongoing (announced on July 30th 2012, April 4th 2013, and May 29th 2013) with pharmaceutical companies and 2 of those are based on Tethadur technology.
Someone forgot to tell the management how many monkeys does it take to test the thing in pre-clinical studies? Or are they all monkeying around?
Entire BOD is a joke. CEO needs to stop writing in blogs, it is a sign of CEOs attempt to manipulate the stock price by inflammatory statements which he does not need to deliver on. Mgmt. team over promises and under delivers. No wonder this stock is sitting around while the BOD and CEO get free shares each year for doing nothing but making false promises.
How about Management returns all free shares for they have received in the last 12 months and refuse to accept any Salary and/or stock options until a deal is done for Tethadur, and the $$$ amount of the deal upfront license payment not total-sales-lifetime number should decide what the stock options and compensation the management gets?
We are investing real hard earned money in this Co. based on what the management says or indicates through their press releases and presentations. It is not a joke and investors have been waiting for a licensing deal since several years now based on the hype management has successfully created over Tethadur platform.
A good CEOs would accept the $1 salary and 0 stock options until they deliver. Sorry you (CEO) must accept a lower pay and feel the pain like all of us (except for those who bought at $0.50).
Only content they have for streaming is what no one wants.
Unless the Management does anything to boost the stock price, this is too cheap and can be manipulated by anyone to come buy it out on the cheap. I am sure Paul and his team will get rewarded one way or the other, but it may not be the case for folks like us. If they announce a big product, and unless the market cap is north of $300M, there is no hope of a big payday. $20, $30 are pipe dreams unless Paul and his Co. do something to change the perception of the Co. and to-date they do not seem to be doing anything to help in fact they seem incapable of doing anything.
I will give it a rest for a month and we can take a check point around mid Dec. to see if they did announce anything.
Just keep in mind the 31 day rule before EOY for a big sell off to come. I just hope the stupid management does announce something to avoid tax loss selling before EOY from hitting the longs hard that would be the management sticking it to the longs hanging by a thread.
Catch you in a month. bye now.....
Are you Bev? Seriously you sound like her. Please give me a timeline of when the Co. got Durasert, and how many products have been approved since chronologically. What that will tell me is how long does it takes the losers to introduce a new product to market (approved).
Secondly, please tell me what you think is going to be the Earnings in 2017 for PSDV? Multiply the number by 10 and discount it by 10% as opposed to what the st. will do in terms of 20%. Now tell me what market cap you think your Co. deserves?
Instead of getting upset with me about not trusting this management and calling them for what they are why dont you look at the facts. Pipeline - nothing in the pipeline is expected in the next 2 years at best. We do not even know if FDA will allow one trial or need multiple trials. That to me is dumb move because they can cost the Co. additional 2 years before they can get in front of the FDA for approval. It implies the product will not get approved until 2018 at best - that is for Medidur. Tethadur is a pipe dream or is it the management blowing smoke up everyone's behind - do not know for sure.
Show me the money!!!
On Wall St. no one cares who is running a Co. operations the best, they care about the growth, earnings and/or perception of it. Anyone on Wall St. really cares what Paul write in his little blog? It is meant to sway small investors into believing the hype created by Paul and Co. I have to admit, I fell for it too and so did everyone else.
Seriously, the only valuation PSDV can get is 10 times Earnings - which at best case will be 10M by 2017 so a market cap of $100M is optimal without discounting. Forget Uveitis and forget Tethadur those products are too far out. Management should be working for free at this stage because they have allowed this ship to take on too much water and the competition is gaining on us, including for Uveitis.
I am long and I resent it but I do not want to lose money - I am hoping for a little pop when they announce a partner for Tethadur if they ever do. Outside of that this Company and its BOD and Paul stink which is the reason this Co. is trading where it is trading and can easily sink into the low 2s.
Keep asking for more freebies Paul - great job.
Anyone care to ask Paul to give a projection of earnings in 2017 will be told we are not giving any revenue guidelines. Ask anyway because a real Co. with products in 12+ countries in EU and an approval in USA should be able to project something 2-3-5 years out. Not these #$%$.
Cause it is fairly valued at this price or lower. Here is why...
1) Illuvien peak sales are expected to be 300M in US and in EU. I think the cost of marketing, advertising and SG&A is going to be in the 250M+ range. i.e. ALIM will possibly make at most $50M in net profits but that is about 2 years out, which means for PSDV at best it is a 10M/year opportunity at best. Nothing much to write home about.
2) Uveitis approval is still 2 years out because the stupid management is dragging its feet. Choice was to go aggressively and have a couple of PIII and maybe get in front of the FDA and get an approval or save about 100M-200M for one trial and beg and hope FDA will allow it. Big unknown for the street is what is FDA going to do? Management is at its mercy and unless there is clarity no one is going to stick their neck out and say 1 trial is going to be sufficient and that the drug/delivery mechanism will be approved in 2016
3) No clarity on Tethadur or its partner - there is no way to size up the opportunity because nothing is known. Even if it was known they are 5-8 years out given the way this stupid Paul and his team are dragging their feet.
4) Competition - cheerleaders are ignoring what the competition is doing. Again the mgmt is too slow, we are passing up opportunities left, right and center in the meantime they are letting opportunities pass them by. Think - this Co. has had products in the market before Eyela and they have been too stupid to push newer products through. Penny wise and pound foolish, they were hoping to be bought out by Pfizer or B&L or someone else which never happened. Instead of positioning the product pipeline so they would have been an attractive acquisition these stupid fools were in a chapel hoping and praying for someone to have pity on them, Winners have a different attitude, this Management team is a lose and they are always going to be defensive and play dead.
So, I hope this answers your question about the valuation.
Some body is getting testy which means I am pressing the right buttons. It does not matter if I sell or short it. I am long and I was long for a reason, I just want the lazy #$%$ management to move or resign and go away. You on the other hand are happy with the pump and dump the mgmt is running.
Stop being such a cheerleader. Ask for a change, maybe you will get it. Better than sulking silently. So, I will hold but I will make life as misserable as possible for the management.
Implies they will probably announce a deal sometime around the AGM. Something to get the cheerleaders all riled up. Take your pencils and calculators out and get ready to make some fast back of the envelope calculations to derive new "perceived" value of PSDV.
Just saying seen this movie too many times.
Desperate for good news - in the meantime the stock takes a beating and the management keeps asking for freebie shares. Stop dreaming.
It does not matter how many will be priced at what - they should get nothing unless you see an appreciation in the stock price and the Co. pipeline improves for real - no false promises.
Withhold all nominees, vote against all proposed increases and allotments to the management they deserve nothing. They should propose a CUT in their pays and total Comp. packages, but they have no shame.
Sorry - delays are never good. Management has dropped the ball big time and they continue to do so. I see the ALIM filing for the CEO pays, bonuses and a golden parachute. I wonder when Paul is going to file something similar for himself.
Big change in the BOD and the CEO/President is required for PSDV to really deliver to the perceived product pipeline. I say perceived because the dumb CEO has created the situation by his stupid blog and created an aura around a product that should not be talked about until you have successfully tested the technology. I am not saying the platform is going to fail, but the management raised the expectations too high and not it is getting out of hand.
There is a reason why CEOs to not blog. Paul has not learned his lesson yet, or maybe he just wants to spread rumors and hype this stock up in which case this is just another over hyped penny stock.
Longs seriously need to start to ask Paul questions and if they are not convinced fire him. We need one big investor to come in and shake things up. Until then this over hyped tethadur platform is a myth CEO is airing and pumping up the investors for.
Ask the genius Paul Ashton to call this the inflection point in the history of PSDV.
Only way this goes up is when they fire the BOD and CEO and force them to take action to accelerate the agenda to introduce products to market faster. To think this guy thinks it was a genius idea to piggy back on Illuvien for Medidur approval does not look so much saner now does it? Illuvien was delayed 3 years and now we are 2 more years or more for Medidur approval. Forget about tethadur because this lame management is still nickle and dimeing the proposals or the value of the paper on which they will write the proposals.
Fire the bunch of idiots running this company and wasting investor money on watching the paint dry for eons.
Sentiment: Strong Sell
And they can dump it almost at will, no one will even know when they dump it onto unsuspecting investors. Seen that movie a 100 times.
Compare the efficacy of Zevalin compared to Rituxan and compare the annual revenue/sales for both drugs. For NHL patients including FL - Zevalin costs $28000 and is a single shot treatment compared to Rituxan which requires 12 shots in 2 years and costs nearly 10 fold.
Health care in USA sucks because doctors are paid upto 6-8% administration cost for drugs. Now apply 6% to 28000 vs 260000 and that is only for the drug admi. cost, 12 consultations vs 1 etc. are other money earners for the Onc/Hem. Do you think they really care for the patients convenience or the cost? Think again.
Wall St. thinks Illuvien is doomed when the smart money saw there was little chance of approval they bid this stock to $8 and shorted all the way up. Now upon approval they would not let the needle go higher than $5.
How many analysts cover Eyela compared to the 3 pathetic losers who showed up for Alimera CC. You would think more would be interested in knowing how Alimera/Illuvien would hurt Eyela sales and if they needed to take Eyela numbers down a bit. Looks like they do not care for this two bit #$%$.
PSDV management is playing dead and enjoying collecting their free money from shareholders, they just need to keep alive and keep the interest alive in PSDV enough to enjoy getting freebee shares, hefty salaries and bonuses. They do not care about the shareholders, at best they will release some PR every once in a wile or Paul will go put out a blog and boost interest in the stock.
it is a penny stock and the Co's management is running it as such. Blood sucking parasites the entire BOD of pSiVida including its Chairman and CEO.
Single shot vs 20 for Eyela is the problem. Doctors love 20 shots. More shots=more $$$ gor the Doctor to sffoard his BMW 5 series or better.